Australian and New Zealand journal of medicine vol:23 issue:6 pages:763-5
Recent angiographic studies after thrombolytic therapy have shown that the rates of effective coronary reperfusion (TIMI grade 3) is still quite low with currently available thrombolytic regimens. Approaches to improving thrombolytic efficacy include the development of mutants of t-PA, recombinant staphylokinase and conjugations of thrombolytic agents to monoclonal antibodies targeted to components of the thrombus. The development of more potent conjugative antithrombolysis therapy includes newer antiplatelet agents and selective thrombin inhibitors such as hirudin and Hirulog. Clinical trials of these new approaches are now underway and hold hope for improvement of reperfusion efficacy in coronary thrombolysis.